724741-75-7 Usage
Uses
Used in Biological Studies:
STF 31 is used as an inhibitor of Glut1 for blocking glucose uptake in cancer cells. This property makes it a valuable tool in the study of cancer cell metabolism and the development of targeted therapies.
Used in Cancer Research:
STF 31 is used as a necrosis inducer for cancer cells that overexpress Glut1, particularly those lacking the von Hippel-Lindau tumor suppressor gene. This application aids in understanding the role of Glut1 in cancer progression and the potential of STF 31 as a therapeutic agent.
Used in Drug Development:
STF 31 is used as a starting point for the development of novel drug delivery systems to enhance its applications and efficacy against cancer cells. Researchers can explore various organic and metallic nanoparticles as carriers for STF 31 delivery, aiming to improve its delivery, bioavailability, and therapeutic outcomes.
Used in Stem Cell Research:
STF 31 is used as a selective elimination agent for human pluripotent stem cells (hPSCs) in mixed cultures. This application can help in the development of stem cell purification techniques and the study of stem cell biology.
Biochem/physiol Actions
STF-31 selectively inhibits the glucose transporter GLUT1 and selectively impairs cancer cell growth of kidney and other types of cancer cells that lack the von Hippel-Lindau (VHL) tumor suppressor protein. Inactivation of VHL increases the activity of hypoxia-inducible factor transcription factor HIF, which in turn stimulates the transcription of genes involved in glucose metabolism, including the GLUT1 gene. VHL-deficient cancer cells, which include about 80% of renal cell carcinomas, are dependent on the high affinity GLUT1 transporter and aerobic glycolysis for ATP production. STF-31 binds directly to the GLUT1 transporter, blocking glucose uptake, resulting in necrosis in VHL-deficient cancer cells, but not in normal cells or cancer cells with intact VHL.
References
1) Chan?et al. (2011),?Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality; Sci. Transl. Med.,?3?94ra70
2) Adams?et al., (2014),?NAMPT is the Cellular Target of STF-31-Like Small-Molecule Probes; ACS Chem. Biol.,?9?2447
3) Dragovich?et al. (2014),?Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphribosyltransferase (NAMPT); Bioorg. Med. Chem. Lett.,?24?954
4)Kraus?et al.?(2018),?Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation; Cell Oncol.(Dordr)?41?485
Check Digit Verification of cas no
The CAS Registry Mumber 724741-75-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,2,4,7,4 and 1 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 724741-75:
(8*7)+(7*2)+(6*4)+(5*7)+(4*4)+(3*1)+(2*7)+(1*5)=167
167 % 10 = 7
So 724741-75-7 is a valid CAS Registry Number.
724741-75-7Relevant academic research and scientific papers
A Red-Light-Activated Ruthenium-Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer Cells
Lameijer, Lucien N.,Ernst, Dani?l,Hopkins, Samantha L.,Meijer, Michael S.,Askes, Sven H. C.,Le Dévédec, Sylvia E.,Bonnet, Sylvestre
, p. 11549 - 11553 (2017/09/11)
We describe two water-soluble ruthenium complexes, [1]Cl2 and [2]Cl2, that photodissociate to release a cytotoxic nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with a low dose (21 J cm?2) of red light in an oxyg
Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities
Bai, Jinhong,Liao, Chenzhong,Liu, Yanghan,Qin, Xiaochu,Chen, Jiaxuan,Qiu, Yatao,Qin, Dongguang,Li, Zheng,Tu, Zheng-Chao,Jiang, Sheng
supporting information, p. 5766 - 5779 (2016/07/06)
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) has the potential to directly limit NAD production in cancer cells and is an effective strategy for cancer treatment. Using a structure-based strategy, we have designed a new class of potent small-molecule inhibitors of NAMPT. Several designed compounds showed promising antiproliferative activities in vitro. (E)-N-(5-((4-(((2-(1H-Indol-3-yl)ethyl)(isopropyl)amino)methyl)phenyl)amino)pentyl)-3-(pyridin-3-yl)acrylamide, 30, bearing an indole moiety, has an IC50 of 25.3 nM for binding to the NAMPT protein and demonstrated promising inhibitory activities in the nanomolar range against several cancer cell lines (MCF-7 GI50 = 0.13 nM; MDA-MB-231 GI50 = 0.15 nM). Triple-negative breast cancer is the most malignant subtype of breast cancer with no effective targeted treatments currently available. Significant antitumor efficacy of compound 30 was achieved (TGI was 73.8%) in an orthotopic MDA-MB-231 triple-negative breast cancer xenograft tumor model. This paper reports promising lead molecules for the inhibition of NAMPT which could serve as a basis for further investigation.
Heteroarylacetic phenylbenzamide, composition and method of use (by machine translation)
-
Paragraph 0176; 0222, (2016/10/08)
Provided are certain heteroaryl benzamides, compositions, and methods of their manufacture and use.
